Sign in
Taking people in United StatesPhase 2

Genetic testing to guide treatment for advanced prostate cancer that resists hormone therapy

Tests whether genetic results can guide treatment choice in advanced castration-resistant prostate cancer.

Key facts

Who runs it
Alliance for Clinical Trials in Oncology
Where
Ames, Bettendorf, Billings, Birmingham, Bloomington, Boston, Brainerd, Brighton, Buffalo, Canton, Chapel Hill, Charleston, Chelsea, Chico, City of Saint Peters, Cleveland, Coeur d'Alene, Colorado Springs, Columbia, Columbus, Creve Coeur, Dallas, Danville, Duluth, Edgewood, Edmonds, Effingham, Encinitas, Eureka, Fargo, Fort Collins, Fort Thomas, Fort Worth, Foxborough, Gaffney, Greeley, Greer, Hackensack, Honolulu, Huntington, Iowa City, Irvine, Jupiter, Kansas City, La Jolla, Lansing, Livonia, Loveland, Marshfield, Mattoon, Mechanicsville, Menomonee Falls, Methuen, Midlothian, Milford, Millville, Milwaukee, Nashville, New York, Newark, O'Fallon, Oak Creek, Oklahoma City, Olathe, Orange, Ottawa, Overland Park, Pekin, Peoria, Peru, Portland, Rehoboth Beach, Richardson, Richmond, Sacramento, Saint Cloud, San Diego, Sayre, Seattle, Shiloh, South Weymouth, Spartanburg, Springfield, St Louis, Stamford, Topeka, Tucson, Union, Urbana, Washington, West Bend, Westwood, and Ypsilanti, United StatesSee the 108 sites
Trial code
Registry title
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Status
Recruiting
Phase
Phase 2
People taking part
474 people, planned
Started
6 Feb 2025
Expected to end
11 Oct 2034
Type of study
Interventional, 3 groups
Treatments tested
  • Genetic testing
  • Valemetostat Tosylate
  • Magnetic Resonance Imaging
  • Computed Tomography
  • Bone scan
  • FDG-Positron Emission Tomography
  • PSMA PET Scan
  • Biospecimen Collection
  • Carboplatin
  • Cabazitaxel
  • Abiraterone Acetate
  • Enzalutamide
  • Lutetium Lu 177 Vipivotide Tetraxetan
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with prostate cancer that has spread and keeps growing despite hormone-lowering treatment. Genetic tests on the tumor decide which study treatment each person gets.

Age
18 years or older
Sex
All sexes
Disease stage
Prostate cancer that has spread (metastatic) and is still growing despite low testosterone (testosterone below 50 ng/dL). Growth is shown by rising PSA, scans or bone scans.
Earlier treatment
Must have had an androgen receptor signaling inhibitor (ARSI). Must have had taxane treatment, unless unable to take it or refusing it. People with BRCA1/2 mutations must have had a PARP inhibitor. No EZH inhibitors before.
Biomarker or test result
Tumor tissue taken within 12 months and a gene test report are needed. A study tumor board uses DNA/RNA changes to assign the treatment. For lutetium Lu 177 vipivotide tetraxetan, the cancer must be PSMA positive.

Main reasons for not taking part

  • Spinal cord compression, or brain metastases unless treated and stable for at least 4 weeks
  • Serious heart problems, such as a heart attack in the last 6 months or heart failure class 3 or 4
  • Uncontrolled high blood pressure (above 160 mmHg systolic or 100 mmHg diastolic)
  • Current use of moderate or strong CYP3A inducers, or known allergy to valemetostat tosylate
  • Major surgery within 4 weeks, or other cancer drugs within the stated recent time windows

The registry criteria, word for word

Show all 45 criteriaShow less

Who can take part

  • PRE-REGISTRATION: Measurable disease and/or non-measurable metastatic disease per RECIST version 1.1
  • PRE-REGISTRATION: Tissue procured within 12 months of pre-registration (metastatic disease preferred over primary tissue, though both are acceptable) available for submission per Section 6.2. For patients who have progressed on A032102 and are pre-registering again, repeat tissue procurement will not be mandated
  • PRE-REGISTRATION: Molecular report available performed as part of standard of care testing via any Clinical Laboratory Improvement Act (CLIA)-certified next generation sequencing (NGS) assay. Patients may be assigned based on pre-determined qualifying molecular/DNA alterations as stated in Section 4.8 after receipt of local molecular testing by the A032102 molecular tumor board (MTB). Final determination of arm assignment will be determined by the MTB. For qualifying DNA alteration determined by the MTB, testing may be from tumor tissue collected at any time or circulating tumor DNA (ctDNA) within 12 months of pre-registration. If no qualifying DNA alteration is identified based on the CLIA-certified next generation sequencing assay and MTB review, Caris testing, should be performed for both DNA/RNA profiling. Arm assignment based RNA requires testing of tumor tissue collected within 12 months of pre-registration and MTB review
  • PRE-REGISTRATION: Age ≥ 18 years
  • REGISTRATION: Progressive mCRPC as defined: 1) castrate levels of serum testosterone \< 50 ng/dL AND one or more of the following criteria (choose all the apply): * PSA progression, defined by at least 2 consecutive rising PSA values at a minimum of 1-week intervals with the most recent PSA value being 2.0 ng/mL or higher, if confirmed PSA rise is the only indication of progression. Patients who received an anti-androgen must have PSA progression after withdrawal of anti-androgen therapy. * Radiographic progression per RECIST 1.1 criteria for soft tissue lesions * Bone metastasis progression per Prostate Cancer Working Group 3 (PCWG3) criteria
  • REGISTRATION: Patients selected to receive lutetium Lu 177 vipivotide tetraxetan treatment are required to have prostate-specific membrane antigen (PSMA) positive mCRPC as determined by investigator assessment. For reference, in the VISION trial this was defined as at least 1 PSMA+ metastatic lesion (defined as uptake greater than that of liver parenchyma in lesions of any size in any organ system) and no PSMA- lesions (defined as uptake equal to or lower than that of liver parenchyma in any lymph node with a short axis of at least 2.5 cm, in any solid organ lesion with a short axis of at least 1.0 cm, or in any bone lesion with a soft-tissue component of at least 1.0 cm in the short axis)
  • REGISTRATION: Prior treatment with androgen receptor signaling inhibitor (ARSI) in either the metastatic hormone sensitive setting or mCRPC is required. Prior taxane therapy in either metastatic hormone sensitive setting or mCRPC is mandated unless patient is taxane ineligible or the patient refuses taxane therapy. Prior lutetium LU177 vipivotide tetraxetan treatment is permitted but not mandated. Patients with known germline or somatic deleterious BRCA 1/2 mutations must have received a prior PARPi
  • REGISTRATION: Resolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, grade ≤ 1 or baseline. Note: Subjects may be enrolled with chronic, stable grade 2 toxicities (defined as no worsening to \> grade 2 for at least 3 months prior to registration and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, comprised of: * Chemotherapy-induced neuropathy * Fatigue * Residual toxicities from prior treatment: Grade 1 or grade 2 endocrinopathies which may include: Hypothyroidism/hyperthyroidism. type I diabetes, hyperglycemia, adrenal insufficiency, adrenalitis, skin hypopigmentation (vitiligo)
  • REGISTRATION: No cytotoxic, biologic, radiopharmaceutical or other non-kinase inhibitor investigational agent within 4 weeks of registration. Treatment with any type of small molecular kinase inhibitor (including investigational kinase inhibitor) within 2 weeks of registration. Treatment with abiraterone acetate, apalutamide, or darolutamide within 2 weeks of registration. Treatment with enzalutamide within 4 weeks of registration. No treatment with radiation therapy within 2 weeks of registration
  • REGISTRATION: No major surgery within 4 weeks of registration
  • REGISTRATION: No prior treatment with EZH inhibitors
  • REGISTRATION: Prior treatment with cabazitaxel + carboplatin
  • REGISTRATION: None of the following conditions: * Current use of moderate or strong cytochrome P450 (CYP)3A inducers. * Known or suspected hypersensitivity to valemetostat tosylate (DS-3201b) or any of the excipients. * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. * HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Imminent or established spinal cord compression based on clinical and/or imaging findings. * Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to registration after radiotherapy or at least 4 weeks prior to registration after major surgery (e.g., removal or biopsy of brain metastasis). Patients must have complete wound healing from major surgery or minor surgery before registration. * Significant cardiovascular defined as: * Myocardial infarction within 6 months prior to enrollment. * Uncontrolled angina pectoris within 6 months prior to enrollment. * New York Heart Association Class 3 or 4 congestive heart failure. * Corrected QT interval calculated by the Fridericia\'s formula (QTcF) ≥ 470 ms per electrocardiogram (ECG) within 42 days before randomization in any individual with any history of any cardiac disease or medication which can impact QTcF. Patients with known history or current symptoms of cardiac disease, history of treatment with cardiotoxic agents, or agents/conditions known to impact QTcF should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification and ECG. * Uncontrolled hypertension (resting systolic blood pressure \>160 mmHg or diastolic blood pressure \> 100 mmHg). * Clinically significant acute infection requiring systemic antibacterial, antifungal or antiviral therapy. * Moderate to severe hepatic impairment (Child-Pugh Class C)
  • REGISTRATION: No freezing or donating sperm ≤ 14 days prior to registration
  • REGISTRATION: Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • REGISTRATION: No granulocyte colony-stimulating factor (GCSF) within 2 weeks of registration
  • REGISTRATION: No red blood cell (RBC) transfusions within 2 weeks of registration
  • REGISTRATION: No platelet transfusions within 2 weeks of registration
  • REGISTRATION: No bleeding diathesis
  • REGISTRATION: White blood cell count (WBC) ≥ 2,500/mcL
  • REGISTRATION: Absolute neutrophil count (ANC) ≥ 1,500/mcL
  • REGISTRATION: Hemoglobin ≥ 9 g/dL
  • REGISTRATION: Platelet count ≥ 100,000/mcL
  • REGISTRATION: Creatinine clearance ≥ 30 mL/min as defined by Cockcroft-Gault equation
  • REGISTRATION: Total bilirubin ≤ 1.5 x ULN (≤ 3 x upper limit of normal [ULN] for subjects with documented Gilbert\'s disease)
  • REGISTRATION: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN
  • REGISTRATION: Albumin ≥ 2.8 g/dL
  • REGISTRATION: The A032102 molecular tumor board will review the local pathology report and molecular sequencing report, and the Alliance registration/randomization office will relay the assignment to the submitting site. Once the site receives this assignment, they can register the patient to A032102. Any questions about the molecular board treatment assignments can be directed to
  • RE-REGISTRATION: Progressive mCRPC (after receiving the tumor board assigned therapy) as defined: 1) castrate levels of serum testosterone \< 50 ng/dL AND 2) progressive disease defined by radiographic progression on conventional imaging (CT/MRI chest, abdomen and pelvis and bone scan within 42 days of re-registration)
  • RE-REGISTRATION: Resolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) resolved to CTCAE version 5.0, grade ≤ 1 or baseline. Note: Subjects may be enrolled with chronic, stable grade 2 toxicities (defined as no worsening to \> grade 2 for at least 3 months prior to registration and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, comprised of: * Chemotherapy-induced neuropathy * Fatigue * Residual toxicities from prior treatment: Grade 1 or grade 2 endocrinopathies which may include: Hypothyroidism/hyperthyroidism. type I diabetes, hyperglycemia, adrenal insufficiency, adrenalitis, skin hypopigmentation (vitiligo)
  • RE-REGISTRATION: None of the following conditions: * Imminent or established spinal cord compression based on clinical and/or imaging findings. * Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to registration after radiotherapy or at least 4 weeks prior to re-registration after major surgery (e.g., removal or biopsy of brain metastasis). Patients must have complete wound healing from major surgery or minor surgery before re-registration. * Corrected QT interval calculated by the Fridericia\'s formula (QTcF) \< 470 ms per ECG within 42 days before randomization in any individual with any history of any cardiac disease or medication which can impact QTcF. * Significant cardiovascular defined as: * Myocardial infarction within 6 months prior to enrollment. * Uncontrolled angina pectoris within 6 months prior to enrollment. * New York Heart Association Class 3 or 4 congestive heart failure. * Uncontrolled hypertension (resting systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg)
  • RE-REGISTRATION: ECOG Performance Status 0-2
  • RE-REGISTRATION: No GCSF within 2 weeks of registration
  • RE-REGISTRATION: No RBC transfusions within 2 weeks of registration
  • RE-REGISTRATION: No platelet transfusions within 2 weeks of registration
  • RE-REGISTRATION: WBC ≥ 2,500/mcL
  • RE-REGISTRATION: ANC ≥ 1,500/mcL
  • RE-REGISTRATION: Hemoglobin ≥ 9 g/dL (transfusions permitted)
  • RE-REGISTRATION: Platelet count ≥ 100,000/mcL
  • RE-REGISTRATION: Creatinine clearance ≥ 30 mL/min as defined by Cockcroft-Gault equation
  • RE-REGISTRATION: Total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for subjects with documented Gilbert\'s disease)
  • RE-REGISTRATION: AST and ALT ≤ 3 x ULN
  • RE-REGISTRATION: Albumin ≥ 2.8 g/dL
  • RE-REGISTRATION: QT Interval (QTcF) \< 470 ms (in individuals with any cardiac history of any medication or condition known to impact QTcF)
  • RE-REGISTRATION: The A032102 molecular tumor board will review the CARIS molecular sequencing report, the Alliance registration/randomization office will relay the assignment to the site. Any questions about the molecular board treatment assignments can be directed to. Exclusion Criteria: -

Where in United States

  • McFarland Clinic - AmesAmes, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
  • University of Iowa Healthcare Cancer Services Quad CitiesBettendorf, United StatesContact: Fernando Maciel Barbosa (principal investigator)Taking people
  • Billings Clinic Cancer CenterBillings, United StatesContact: John M. Schallenkamp (principal investigator)Taking people
  • University of Alabama at Birmingham Cancer CenterBirmingham, United StatesContact: Joelle Hamilton (principal investigator)Taking people
  • Illinois CancerCare-BloomingtonBloomington, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Dana-Farber Cancer InstituteBoston, United StatesContact: Rana McKay, MDNo longer taking part
  • Essentia Health Saint Joseph's Medical CenterBrainerd, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Trinity Health IHA Medical Group Hematology Oncology - BrightonBrighton, United StatesContact: Elie G. Dib (principal investigator)Taking people
  • Roswell Park Cancer InstituteBuffalo, United StatesContact: Ellis G. Levine (principal investigator)Taking people
  • Illinois CancerCare-CantonCanton, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Trinity Health IHA Medical Group Hematology Oncology - CantonCanton, United StatesContact: Elie G. Dib (principal investigator)Taking people
  • UNC Lineberger Comprehensive Cancer CenterChapel Hill, United StatesContact: Catherine Fahey (principal investigator)Taking people
  • Vandalia Health/CAMC Institute for Academic MedicineCharleston, United StatesContact: Rana McKay, MDNo longer taking part
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea, United StatesContact: Elie G. Dib (principal investigator)Taking people
  • Enloe Medical CenterChico, United StatesContact: Nicholas Mitsiades (principal investigator)Taking people
  • Siteman Cancer Center at Saint Peters HospitalCity of Saint Peters, United StatesContact: Eric M. Knoche (principal investigator)Taking people
  • MetroHealth Medical CenterCleveland, United StatesContact: Joseph Attallah (principal investigator)Taking people
  • Kootenai Health - Coeur d'AleneCoeur d'Alene, United StatesContact: Rana McKay, MDNo longer taking part
  • Memorial Hospital NorthColorado Springs, United StatesContact: Steven R. Schuster (principal investigator)Taking people
  • UCHealth Memorial Hospital CentralColorado Springs, United StatesContact: Steven R. Schuster (principal investigator)Taking people
  • MU Health - University Hospital/Ellis Fischel Cancer CenterColumbia, United StatesContact: Rana McKay, MDNo longer taking part
  • Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Timothy D. Gauntner (principal investigator)Taking people
  • Siteman Cancer Center at West County HospitalCreve Coeur, United StatesContact: Eric M. Knoche (principal investigator)Taking people
  • UT Southwestern Simmons Cancer Center - RedBirdDallas, United StatesContact: Joseph Vento (principal investigator)Taking people
  • UT Southwestern/Simmons Cancer Center-DallasDallas, United StatesContact: Joseph Vento (principal investigator)Taking people
  • Parkland Memorial HospitalDallas, United StatesContact: Rana McKay, MDNo longer taking part
  • Carle at The RiverfrontDanville, United StatesContact: Priyank P. Patel (principal investigator)Taking people
  • Essentia Health Cancer CenterDuluth, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Saint Elizabeth Healthcare EdgewoodEdgewood, United StatesContact: Matthew Kurian (principal investigator)Taking people
  • Swedish Cancer Institute-EdmondsEdmonds, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Carle Physician Group-EffinghamEffingham, United StatesContact: Priyank P. Patel (principal investigator)Taking people
  • UC San Diego Health System - EncinitasEncinitas, United StatesContact: Rana R. McKay (principal investigator)Taking people
  • Illinois CancerCare-EurekaEureka, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Essentia Health Cancer Center-South University ClinicFargo, United StatesContact: Bret E. Friday (principal investigator)Taking people
  • Cancer Care and Hematology-Fort CollinsFort Collins, United StatesContact: Steven R. Schuster (principal investigator)Taking people
  • Poudre Valley HospitalFort Collins, United StatesContact: Steven R. Schuster (principal investigator)Taking people
  • Saint Elizabeth Healthcare Fort ThomasFort Thomas, United StatesContact: Rana McKay, MDNo longer taking part
  • UT Southwestern/Simmons Cancer Center-Fort WorthFort Worth, United StatesContact: Joseph Vento (principal investigator)Taking people
  • Dana-Farber Cancer Institute at FoxboroughFoxborough, United StatesContact: Daniel Roberts (principal investigator)Taking people
  • Gibbs Cancer Center-GaffneyGaffney, United StatesContact: Michael Humeniuk (principal investigator)Taking people
  • UCHealth Greeley HospitalGreeley, United StatesContact: Steven R. Schuster (principal investigator)Taking people
  • Gibbs Cancer Center-PelhamGreer, United StatesContact: Michael Humeniuk (principal investigator)Taking people
  • Hackensack University Medical CenterHackensack, United StatesContact: Robert S. Alter (principal investigator)Taking people
  • Tripler Army Medical CenterHonolulu, United StatesContact: Karen J. Shou (principal investigator)Taking people
  • Edwards Comprehensive Cancer CenterHuntington, United StatesContact: Toni O. Pacioles (principal investigator)Taking people
  • University of Iowa/Holden Comprehensive Cancer CenterIowa City, United StatesContact: Fernando Maciel Barbosa (principal investigator)Taking people
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareIrvine, United StatesContact: Rana McKay, MDNo longer taking part
  • Jupiter Medical CenterJupiter, United StatesContact: Ryan H. Devine (principal investigator)Taking people
  • University of Kansas Cancer CenterKansas City, United StatesContact: Elizabeth M. Wulff (principal investigator)Taking people
  • UC San Diego Moores Cancer CenterLa Jolla, United StatesContact: Rana R. McKay (principal investigator)Taking people
  • University of Michigan Health - Sparrow LansingLansing, United StatesContact: Elie G. Dib (principal investigator)Taking people
  • Trinity Health Saint Mary Mercy Livonia HospitalLivonia, United StatesContact: Elie G. Dib (principal investigator)Taking people
  • Medical Center of the RockiesLoveland, United StatesContact: Steven R. Schuster (principal investigator)Taking people
  • Marshfield Medical Center-MarshfieldMarshfield, United StatesContact: Michael Husak (principal investigator)Taking people
  • Carle Physician Group-Mattoon/CharlestonMattoon, United StatesContact: Priyank P. Patel (principal investigator)Taking people
  • Bon Secours Memorial Regional Medical CenterMechanicsville, United StatesContact: Joseph D. Pennington (principal investigator)Taking people
  • Froedtert Menomonee Falls HospitalMenomonee Falls, United StatesContact: Kathryn A. Bylow (principal investigator)Taking people
  • Dana Farber-Merrimack ValleyMethuen, United StatesContact: Pedro M. Sanz-Altamira (principal investigator)Taking people
  • Bon Secours Saint Francis Medical CenterMidlothian, United StatesContact: Joseph D. Pennington (principal investigator)Taking people
  • Dana-Farber/Brigham and Women's Cancer Center at Milford RegionalMilford, United StatesContact: Daniel E. Fein (principal investigator)Taking people
  • Beebe South Coastal Health CampusMillville, United StatesContact: Gregory A. Masters (principal investigator)Taking people
  • Medical College of WisconsinMilwaukee, United StatesContact: Kathryn A. Bylow (principal investigator)Taking people
  • Vanderbilt University/Ingram Cancer CenterNashville, United StatesContact: Rana McKay, MDNo longer taking part
  • Mount Sinai HospitalNew York, United StatesContact: Eric J. Miller (principal investigator)Taking people
  • Helen F Graham Cancer CenterNewark, United StatesContact: Gregory A. Masters (principal investigator)Taking people
  • Medical Oncology Hematology Consultants PANewark, United StatesContact: Gregory A. Masters (principal investigator)Taking people
  • Cancer Care Center of O'FallonO'Fallon, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Drexel Town Square Health CenterOak Creek, United StatesContact: Kathryn A. Bylow (principal investigator)Taking people
  • University of Oklahoma Health Sciences CenterOklahoma City, United StatesContact: Adanma Anji Ayanambakkam Attanathi (principal investigator)Taking people
  • The University of Kansas Cancer Center - OlatheOlathe, United StatesContact: Elizabeth M. Wulff (principal investigator)Taking people
  • UC Irvine Health- Chao Family Comprehensive Cancer CenterOrange, United StatesContact: Rana McKay, MDNo longer taking part
  • Illinois CancerCare-Ottawa ClinicOttawa, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • University of Kansas Hospital-Indian Creek CampusOverland Park, United StatesContact: Elizabeth M. Wulff (principal investigator)Taking people
  • Illinois CancerCare-PekinPekin, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Illinois CancerCare-PeoriaPeoria, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Illinois CancerCare-PeruPeru, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Oregon Health and Science UniversityPortland, United StatesContact: Alexandra O. Sokolova (principal investigator)Taking people
  • Providence Portland Medical CenterPortland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Providence Saint Vincent Medical CenterPortland, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Beebe Health CampusRehoboth Beach, United StatesContact: Gregory A. Masters (principal investigator)Taking people
  • UT Southwestern Clinical Center at Richardson/PlanoRichardson, United StatesContact: Joseph Vento (principal investigator)Taking people
  • Bon Secours Cancer Institute at Reynolds CrossingRichmond, United StatesContact: Joseph D. Pennington (principal investigator)Taking people
  • Bon Secours Richmond Community HospitalRichmond, United StatesContact: Joseph D. Pennington (principal investigator)Taking people
  • Bon Secours Saint Mary's HospitalRichmond, United StatesContact: Joseph D. Pennington (principal investigator)Taking people
  • VCU Massey Cancer Center at Stony PointRichmond, United StatesContact: John Melson (principal investigator)Taking people
  • VCU Massey Comprehensive Cancer CenterRichmond, United StatesContact: John Melson (principal investigator)Taking people
  • University of California Davis Comprehensive Cancer CenterSacramento, United StatesContact: Nicholas Mitsiades (principal investigator)Taking people
  • Coborn Cancer Center at Saint Cloud HospitalSaint Cloud, United StatesContact: Donald J. Jurgens (principal investigator)Taking people
  • UC San Diego Medical Center - HillcrestSan Diego, United StatesContact: Rana R. McKay (principal investigator)Taking people
  • Guthrie Medical Group PC-Robert Packer HospitalSayre, United StatesContact: Rana McKay, MDNo longer taking part
  • Swedish Medical Center-First HillSeattle, United StatesContact: Alison K. Conlin (principal investigator)Taking people
  • Memorial Hospital EastShiloh, United StatesContact: Eric M. Knoche (principal investigator)Taking people
  • Dana-Farber/Brigham and Women's Cancer Center at South ShoreSouth Weymouth, United StatesContact: Thomas P. O'Connor (principal investigator)Taking people
  • Spartanburg Medical CenterSpartanburg, United StatesContact: Michael Humeniuk (principal investigator)Taking people
  • Baystate Medical CenterSpringfield, United StatesContact: John C. McCann (principal investigator)Taking people
  • Siteman Cancer Center at Christian HospitalSt Louis, United StatesContact: Eric M. Knoche (principal investigator)Taking people
  • Siteman Cancer Center-South CountySt Louis, United StatesContact: Eric M. Knoche (principal investigator)Taking people
  • Washington University School of MedicineSt Louis, United StatesContact: Eric M. Knoche (principal investigator)Taking people
  • Stamford Hospital/Bennett Cancer CenterStamford, United StatesContact: Anthony P. Gulati (principal investigator)Taking people
  • University of Kansas Health System Saint Francis CampusTopeka, United StatesContact: Elizabeth M. Wulff (principal investigator)Taking people
  • Banner University Medical Center - TucsonTucson, United StatesContact: Edward P. Gelmann (principal investigator)Taking people
  • University of Arizona Cancer Center-North CampusTucson, United StatesContact: Edward P. Gelmann (principal investigator)Taking people
  • SMC Center for Hematology Oncology UnionUnion, United StatesContact: Michael Humeniuk (principal investigator)Taking people
  • Carle Cancer CenterUrbana, United StatesContact: Priyank P. Patel (principal investigator)Taking people
  • Illinois CancerCare - WashingtonWashington, United StatesContact: Bryan A. Faller (principal investigator)Taking people
  • Froedtert West Bend Hospital/Kraemer Cancer CenterWest Bend, United StatesContact: Kathryn A. Bylow (principal investigator)Taking people
  • University of Kansas Hospital-Westwood Cancer CenterWestwood, United StatesContact: Elizabeth M. Wulff (principal investigator)Taking people
  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti, United StatesContact: Elie G. Dib (principal investigator)Taking people

About the trial

What the trial wants to find out

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. Valemetostat tosylate is in a class of medications called EZH1/EZH2 inhibitors. It blocks proteins called EZH1 and EZH2, which may help slow or stop the spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Cabazitaxel injection is in a class of medications called microtubule inhibitors. It works by slowing or stopping the growth of tumor cells. Abiraterone acetate blocks tissues from making androgens (male hormones), such as testosterone. This may cause the death of tumor cells that need androgens to grow. It is a type of anti-androgen. Enzalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Lutetium Lu 177 vipivotide tetraxetan is in a class of medications called radiopharmaceuticals. It works by targeting and delivering radiation directly to tumor cells which damages and kills these cells. Assigning patients to targeted treatment based on genetic testing may help shrink or slow the cancer from growing

The 3 groups in the trial

  • Arm A (genetic testing, valemetostat tosylate)Treatment being tested

    Patients undergo genetic testing on previously-collected tissue samples. Patients receive valemetostat tosylate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT and bone scan throughout the trial. Patients may also undergo optional FDG or PSMA PET, as well as optional blood collection throughout the trial.

    Treatment: Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging, Computed Tomography, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, and Biospecimen Collection

  • Arm B (genetic testing, carboplatin, cabazitaxel)Treatment being tested

    Patients undergo genetic testing on previously-collected tissue samples. Patients receive carboplatin IV over 30 minutes and cabazitaxel IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT and bone scan throughout the trial. Patients may also undergo optional FDG or PSMA PET, as well as optional blood collection throughout the trial.

    Treatment: Genetic testing, Magnetic Resonance Imaging, Computed Tomography, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, Biospecimen Collection, Carboplatin, and Cabazitaxel

  • Arm C (genetic testing, physician choice treatment)Treatment being tested

    Patients undergo genetic testing on previously-collected tissue. Patients receive one of the following treatment regimens per treating physician: 1)Cabazitaxel IV over 60 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. 2)Abiraterone acetate PO QD on days 1-28 of each cycle and prednisone PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. 3) Enzalutamide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. 4) Lutetium Lu 177 vipivotide tetraxetan IV on day 1 of each cycle. Treatment repeats every 42 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI or CT and bone scan throughout the trial. Patients may also undergo optional FDG or PSMA PET, as well as optional blood collection throughout the trial.

    Treatment: Genetic testing, Magnetic Resonance Imaging, Computed Tomography, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, Biospecimen Collection, Cabazitaxel, Abiraterone Acetate, Enzalutamide, and Lutetium Lu 177 Vipivotide Tetraxetan

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
Plain-language title
Genetic testing to guide treatment for advanced prostate cancer that resists hormone therapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
3 November 2026